本帖最后由 老马 于 2012-1-13 21:20 编辑
$ [6 y; C. r! F$ U
* @/ n8 T- j& o& p5 E爱必妥和阿瓦斯丁的比较
' p8 \7 v9 \: O3 r
- l7 l1 n* Y, Z3 ^# |0 H* o5 _. Z6 bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
; Y8 I+ P4 k& k
$ f8 H! k3 G% l; W5 \; S U0 f( o
& P% j/ @5 c: ~3 V' Fhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/% n4 z1 U3 G$ N4 e# e- I
==================================================
; e- u4 o7 y KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 m! E, n7 h; j* dPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., L# `3 p( S3 m( Z. s& }
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.& g# r. n/ e% D4 w
|